A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of S-Adenosyl-l-Methionine (SAMe) Versus Escitalopram in Major Depressive Disorder

Clicks: 183
ID: 272467
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #64 of 273 articles by views in the journal of clinical psychiatry

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Article Abstract Objective: To examine the comparative antidepressant efficacy of S-adenosyl-l-methionine (SAMe) and escitalopram in a placebo-controlled, randomized, double-blind clinical trial. Method: One hundred eighty-nine outpatients (49.7% female, mean [SD] age = 45 [15] years) with DSM-IV-diagnosed major depressive disorder (MDD) were recruited from April 13, 2005, to December 22, 2009, at the Massachusetts General Hospital and at Butler Hospital. Patients were randomized for 12 weeks to SAMe 1,600-3,200 mg/d, escitalopram 10-20 mg/d, or placebo. Doses were escalated at 6 weeks in the event of nonresponse. The main outcome measure was the 17-item Hamilton Depression Rating Scale (HDRS-17). Tolerability was assessed by the Systematic Assessment for Treatment of Emergent Events-Specific Inquiry (SAFTEE-SI). Results: All 3 treatment arms demonstrated a significant improvement of about 5-6 points in HDRS-17 scores (P < .001 for all), and no significant differences were observed between the treatment arms (P > .05 for all). Response rates in the intent-to-treat sample were 36% for SAMe, 34% for escitalopram, and 30% for placebo. Remission rates were 28% for SAMe, 28% for escitalopram, and 17% for placebo. No comparisons between treatment groups attained significance (P > .05 for all). Tolerability was good, with gastrointestinal side effects (19% for stomach discomfort and 20% for diarrhea) as the most common in the SAMe arm. Significant differences were observed between treatment groups for dizziness, anorgasmia, diminished mental acuity, and hot flashes (P < .05 for all). Conclusions: The results fail to support an advantage over placebo for either the investigational treatment SAMe or the standard treatment escitalopram for MDD. Trial Registration: ClinicalTrials.gov identifier: NCT00101452 J Clin Psychiatry © Copyright 2013 Physicians Postgraduate Press, Inc. Submitted: May 17, 2013; accepted August 27, 2013. Online ahead of print: December 24, 2013 (doi:10.4088/JCP.13m08591). Corresponding author: David Mischoulon, MD, PhD, 1 Bowdoin Sq, 6th Floor, Massachusetts General Hospital, Boston, MA 02114 (dmischoulon@partners.org).
Reference Key
mischoulon2013thea Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors David Mischoulon;Lawrence H. Price;Linda L. Carpenter;Audrey R. Tyrka;George I. Papakostas;Lee Baer;Christina M. Dording;Alisabet J. Clain;Kelley Durham;Rosemary Walker;Elizabeth Ludington;Maurizio Fava;
Journal the journal of clinical psychiatry
Year 2013
DOI
DOI not found
URL
https://www.psychiatrist.com/jcp/depression/double-blind-randomized-placebo-controlled-clinical/
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.